HomeVCEL • NASDAQ
add
Vericel Corp
Previous close
$43.86
Day range
$43.05 - $44.50
Year range
$29.24 - $53.05
Market cap
2.09B USD
Avg Volume
450.08K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 65.00M | 23.35% |
Operating expense | 35.78M | 11.23% |
Net income | 12.99M | 119.40% |
Net profit margin | 19.99 | 77.85% |
Earnings per share | 0.26 | 100.00% |
EBITDA | 13.88M | 94.83% |
Effective tax rate | 7.81% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 109.56M | -8.35% |
Total assets | 353.66M | 29.54% |
Total liabilities | 127.70M | 58.19% |
Total equity | 225.95M | — |
Shares outstanding | 48.29M | — |
Price to book | 9.29 | — |
Return on assets | 9.48% | — |
Return on capital | 10.55% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 12.99M | 119.40% |
Cash from operations | 10.09M | 44.60% |
Cash from investing | -8.09M | 62.78% |
Cash from financing | 1.31M | 116.03% |
Net change in cash | 3.30M | 123.36% |
Free cash flow | 5.61M | -51.77% |
About
Vericel Corporation is a public, American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.
In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts. Wikipedia
Founded
1989
Headquarters
Website
Employees
314
